University of Vermont

The University of Vermont Cancer Center


Head and Neck Cancer Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on head and neck cancer research.

Status: Active - Recruiting
Study Title:
VCC 0905 – A Pilot Study of Evaluate Response to Neoadjuvant Chemotherapy with Cisplatin and Docetaxel Followed by Chemoradiation Therapy with Carboplatin in Stage IV Non-Metastatic Head and Neck Cancer
Purpose: The purpose of this study is to evaluate the effectiveness of neoadjuvant chemotherapy (chemotherapy given before radiotherapy) using cisplatin and docetaxel followed by carboplatin chemotherapy  given at the same time as radiotherapy in the treatment of head and neck cancer.  Some studies have used neoadjuvant chemotherapy with 3 drugs (cisplatin, docetaxel and 5-fluorouracil) to try to shrink the tumor before  radiation therapy. However such intense chemotherapy may be associated with significant toxicity. We will be testing neoadjuvant chemotherapy with only two drugs (cisplatin and docetaxel) followed by chemoradiation therapy with only carboplatin to evaluate if tumor response can be achieved with less toxicity. Identifier: NCT00982436
Primary/Site/Co Investigator: Julie Olin, MD
Contact: Karen Wilson (802) 656-4101
Institution Number: CHRMS M09-269, VCC 0905
Protocol Research Type: Investigator Initiated
Status: Active - Closed to Accrual
Study Title: An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (Zactima) versus Placebo in Subjects with Unresectable, Locally Advanced or Metastatic Medullary Thyroid Cancer. 
Purpose: The purpose of this study is to demonstrate an improvement in progression-free survival with ZD6474 as compared to placebo.  This study will find out more about how subjects will react to the drug, what happens to ZD6474 in the human body, the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors. Identifier: NCT00410761
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Kate Murray (802) 656-9401
Institution Number: M07-084
Protocol Research Type: Industry Sponsored

Last modified July 10 2015 02:26 PM